ub.xmlui.mirage2.page-structure.muninLogoub.xmlui.mirage2.page-structure.openResearchArchiveLogo
    • EnglishEnglish
    • norsknorsk
  • Velg spraaknorsk 
    • EnglishEnglish
    • norsknorsk
  • Administrasjon/UB
Vis innførsel 
  •   Hjem
  • Universitetsbiblioteket
  • Artikler, rapporter og annet (UB)
  • Vis innførsel
  •   Hjem
  • Universitetsbiblioteket
  • Artikler, rapporter og annet (UB)
  • Vis innførsel
JavaScript is disabled for your browser. Some features of this site may not work without it.

Vaccines and Immunostimulants for finfish

Permanent lenke
https://hdl.handle.net/10037/20338
DOI
https://doi.org/10.3389/fimmu.2020.573771
Thumbnail
Åpne
article.pdf (119.0Kb)
Publisert versjon (PDF)
Dato
2020-09-29
Type
Journal article
Tidsskriftartikkel
Peer reviewed

Forfatter
Munang´andu, Hetron Mweemba; Salinas, I.; Tafalla, Carolina; Dalmo, Roy Ambli
Sammendrag
Following a successful renal transplantation circulating markers of inflammation may remain elevated, and systemic inflammation is associated with worse clinical outcome in renal transplant recipients (RTRs). Vitamin D-receptor (VDR) activation is postulated to modulate inflammation and endothelial function. We aimed to explore if a synthetic vitamin D, paricalcitol, could influence systemic inflammation and immune activation in RTRs. Newly transplanted RTRs were included in an open-label randomized controlled trial on the effect of paricalcitol on top of standard care over the first post-transplant year. Fourteen pre-defined circulating biomarkers reflecting leukocyte activation, endothelial activation, fibrosis and general inflammatory burden were analyzed in 74 RTRs at 8 weeks (baseline) and 1 year post-engraftment. Mean changes in plasma biomarker concentrations were compared by t-test. The expression of genes coding for the same biomarkers were investigated in 1-year surveillance graft biopsies (n = 60). In patients treated with paricalcitol circulating osteoprotegerin levels increased by 0.19 ng/ml, compared with a 0.05 ng/ml increase in controls (p = 0.030). In graft tissue, a 21% higher median gene expression level of TNFRSF11B coding for osteoprotegerin was found in paricalcitol-treated patients compared with controls (p = 0.026). Paricalcitol treatment did not significantly affect the blood- or tissue levels of any other investigated inflammatory marker. In RTRs, paricalcitol treatment might increase both circulating and tissue levels of osteoprotegerin, a modulator of calcification, but potential anti-inflammatory treatment effects in RTRs are likely very modest.
Forlag
Frontiers Media
Sitering
Munang´andu Hetron, Salinas I, Tafalla C, Dalmo RA. Vaccines and Immunostimulants for finfish. Frontiers in Immunology. 2020
Metadata
Vis full innførsel
Samlinger
  • Artikler, rapporter og annet (UB) [3260]
Copyright 2020 The Author(s)

Bla

Bla i hele MuninEnheter og samlingerForfatterlisteTittelDatoBla i denne samlingenForfatterlisteTittelDato
Logg inn

Statistikk

Antall visninger
UiT

Munin bygger på DSpace

UiT Norges Arktiske Universitet
Universitetsbiblioteket
uit.no/ub - munin@ub.uit.no

Tilgjengelighetserklæring